Thixo-viscoelastoplastic rheological characterisation of human mucus using a multimode BMP constitutive equation approach

Michelle Figueroa-Landeta, Sarahí L. Esponda-Cervantes, M. Fernanda Reyes-Tenorio, Octavio Manero, J. Esteban López-Aguilar · 2025

Read Thixo-viscoelastoplastic rheological characterisation of human mucus using a multimode BMP constitutive equation approach by Michelle Figueroa-Landeta, Sarahí L. Esponda-Cervantes, M. Fernanda Reyes-Tenorio, Octavio Manero, J. Esteban López-Aguilar (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12706075.txt.

Introduction

Michelle Figueroa-Landeta and four co-authors model how human mucus flows and stretches, in a research paper from 2025. Mucus from healthy people behaves in a complex way: it can flow, spring back, and change with time. Mucus from people with cystic fibrosis or chronic lung disease behaves in other ways.

The team fits a math model to lab tests of mucus under steady and unsteady shearing. The model matches the real behavior well. It then predicts how mucus acts when stretched, which matters for coughing it clear. The authors say these flow traits could one day serve as markers of illness or of how well a treatment works.

Catalog record

CREATORMichelle Figueroa-Landeta, Sarahí L. Esponda-Cervantes, M. Fernanda Reyes-Tenorio, Octavio Manero, J. Esteban López-Aguilar
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE318 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12706075

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Thixo-viscoelastoplastic rheological characterisation of human mucus using a multimode BMP constitutive equation approach Authors: Michelle Figueroa-Landeta, Sarahí L. Esponda-Cervantes, M. Fernanda Reyes-Tenorio, Octavio Manero, J. Esteban López-Aguilar Published: 2025 ABSTRACT In this work, the most recent Bautista-Manero-Puig (BMP) constitutive model-variant, i.e., the BMP+\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\_\tau _p$$\end{document} rheological equation-of-state, is used as a theoretical approach to describe the thixo-viscoelastoplastic characteristics of human mucus-sputum in rheometric flows, focused on healthy, Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD) affected samples, to determine its mechanical-to-biological response interplay. The BMP+\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\_\tau _p$$\end{document} model reproduces quantitatively the mucus-sputum rheological behaviour in steady and unsteady shearing flows under conventional protocols. From such theoretical characterisation, predictions are presented for LAOS and uniaxial extension, evidencing that thixotropy impacts strongly on sputum rheological behaviour. On plasticity and thixotropy, an explicit inverse relationship between a fluidisation stress and the BMP+\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\_\tau _p$$\end{document} thixotropic parameters is found and tested against independent measurements, giving: (i) quantitative agreement with medical reports; and (ii) evidence of a highly non-linear internal-structure rearrangement under LAOS. In the scarcely-treated mucus-sputum extensional deformations, BMP+\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\_\tau _p$$\end{document} predictions provide a rheological signature as augmented strain-hardening extensional-viscosity peaks: an additional source of flow-resistance in expectoration processes, with mixed shear-to-extensional flows. This may serve as: (i) an advanced rheological basis for biomarker development to determine the patient state, (ii) a tool for the efficacy-of-treatment evaluation with potential application for newly-emerging illnesses, e.g., COVID-19, closely-related with CF in sputum consistency and symptoms. Introduction Mucus is a secretion that serves different functions for organs and glands in living systems, e.g., expelling of external micro-particles, hindering access of noxious agents to the epithelium and, in the respiratory tract, forming a selectively permeable layer for the diffusion and exchange of gases, and tissue lubrication1. Mucus composition consists of about 1% weight of salts or electrolytes, 0.5% - 1% of free proteins, 1% -5% mucin glycoproteins (mucins), and 97% water2–4. Also, bronchial mucus contains a significant proportion of lipids and, in pathological states, can also contain DNA and traces of other proteins coming from ruptured leukocytes3. Such composition confers non-Newtonian characteristics to mucus, particularly due to a somewhat complex protein-entanglement process5, i.e., (i) in general, protein concentration increases viscosity; (ii) mucin covalent networked bonds confer mucus its viscoelastic properties6,7; (iii) mucin clusters strengthened by non-mucin proteins generate a finite yield stress8,9; and (iv) the three-dimensional structure of the protein network correlates with time-dependent rheological properties, such as thixotropy10–12. We encourage our readers to see a broader explanation of mucin network characteristics, evolution and factors modifying its rheological nature in the work of Georgiades et al.13, Kavishvar & Ramachandran9, Wagner et al.14, and Esteban-Enjuto et al.15,16 Consequently, any affectation upon such network will lead to different complex rheological responses, which may be broadly classified as thixo-viscoelastoplastic (TVEP)8. Mucus rheological characterisation may help to understand its role within the human body5,11,17–20. For example, respiratory mucociliary clearance relies on the rheological qualities of mucus, which modulate the transport processes between the cilia layers21. Furthermore, the rheological features of mucus may serve as biomarkers for respiratory disease diagnosis and monitoring18, even as predictors for clinical outcomes22–25, considering that respiratory diseases alter the usual concentration of proteins through antibody presence, strengthening the mucin network and changing the mucus flow properties25. However, sputum specimen collection (which is a mixture of saliva and mucus, coughed up from the respiratory tract) typically results in a non-invasive and straightforward procedure compared to obtaining mucus samples26. This is why most of research in the field of rheological characterisation is done upon sputum5,11,17–19. However, in some clinical settings, a more intensive approach may be necessary when patients have difficulty in expelling fluid from the upper respiratory tract26. Like any ideal biomarker, those based on rheometric measurements must be reproducible, clinically relevant, sensitive, reliable, and easy to obtain27, aspects not yet fulfilled because of the lack of consensus on the experimental protocols and the pieces of information needed to understand and differentiate the complex rheological response of sputum. Nonetheless, rheological biomarkers present some advantages over conventional ones, such as being cost and time-efficient17, even standing as a non-invasive alternative to predict clinical symptoms22. Two diseases whose study continues in the spotlight regarding their biomarker improvement are Chronic Obstructive Pulmonary Disease (COPD) and COVID-1928,29. According to the World Health Organization30, one of the most common chronic respiratory diseases is COPD, which is the third leading cause of death worldwide. COPD symptoms include coughing, difficulty of breathing, wheezing, and tiredness, which leads to restricted airflow30. Besides, the lungs can get damaged or clogged with phlegm30. On the other hand, the COVID-19 disease has persisted as a worldwide health issue since the pandemic began and still calls for long term sustained prevention, controlling and management activities9,31. Severe Acute Respiratory Failure (SARS) is one of COVID-19 main complications. SARS is characterised by mucus hypersecretion and high viscosity sputum, resulting in chronic lung-clogging, inflammation and airway obstruction, accompanied with excessive bacterial growth and lack of proper oxygenation in the worst cases17,32. The flow properties of COVID-19 mucus are reported to be comparable in quality and intensity to those of Cystic Fibrosis (CF)9. Indeed, such intense growth of the sputum consistency is apparent in CF that its medical designation as mucoviscidosis reflects its critical condition of development19. Then, derived from the lack of recent studies reporting a thorough rheological characterisation of COVID-19 patients sputum - being, to the best of our knowledge, the work of Kratochvil et al.9 the only one dealing with such rather new respiratory illness-, one way to explore the rheological response of COVID-19 sputum is to study CF samples instead. In Table 1, the most common biomarkers for COPD and CF are summarised, emphasizing on the type of biomarker, its characteristics and its utility in determining illness-state and treatment, if applicable. Mostly, they serve to determine severity and prognosis of respiratory disease33,34, to monitor the therapeutic response under specific treatments35, and to determine the occurrence of disease exacerbations36 (defined as a sustained worsening of symptoms, that has an acute onset and requires a change in the patients treatment37). Some of them are directly related to major symptoms, e.g. the Forced Expiratory Volume in one second (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$FEV_1$$\end{document}), yet they are not exclusively used for either COPD or CF, but provide key information on the patient state, e.g., Clara cell protein (CC16)38.Table 1Typical COPD and CF biomarkers.BiomarkerIllnessClassificationCharacteristicsForced Expiratory Volume in 1 second (\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$FEV_1$$\end{document})COPD, CFSeverity and prognosisMeasures lung activity and air flow. Reduction, irreversibility and chronicity of the \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$FEV_1$$\end{document} differentiate COPD and CF33,34.Exhaled Breath Condensate (EBC)COPDExacerbationsRecollected by cooling exhaled air. pH of EBC from COPD patients is lower than that of healthy individuals, providing a biomarker based on the acidity of the breath condensate27.NeutrophilsCOPD, CFExacerbationsThese are inflammatory cells which activity serve to monitor lung function. They are related to airway obstruction, mucus hypersecretion and alveolar destruction.35,36,39C-Reactive Protein (CRP)COPDPrognosis, mortality and exacerbationsThis protein takes part

Read the complete text